Skip to main content
. Author manuscript; available in PMC: 2011 Apr 14.
Published in final edited form as: Mol Cell Pharmacol. 2010;2(5):191–202.

Figure 6. Sensitizing ER-negative breast cancer cells to endocrine therapy.

Figure 6

ER can be reactivated in ER-negative breast cancer cells using a combination of therapies. Reactivated ER can be targeted with tamoxifen. Tamoxifen bound reactivated ER recruits compressor complexes resulting in modulation of ER-responsive gene expression.